/MYNDF

MYNDF Stock - MYND Life Sciences Inc.

Q: What is the analyst price target for MYNDF?

Analyst price target information is not currently available for MYNDF.

Q: What is MYNDF's market cap?

Market capitalization information is not currently available for MYNDF.

Healthcare|Biotechnology|OTC

$0.01+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.01

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for MYNDF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.10

52W High$0.07

52W Low$0.01

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	$92,990	N/A	N/A	N/A	N/A
Gross Profit	$-240,000	$-180,000	N/A	N/A	N/A
Gross Margin	-258.1%	N/A	N/A	N/A	N/A
Operating Income	$-1,828,763	$-3,003,466	$-4,291,579	$-56,466	$-2,535
Net Income	$-1,517,860	$-3,567,322	$-4,367,198	$-56,466	$-2,535
Net Margin	-1632.3%	N/A	N/A	N/A	N/A
EPS	$-0.03	$-0.08	$-0.10	$-0.00	$-0.00

Company Overview

MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs. The company is headquartered in Kelowna, Canada.

Visit Website